Mothers raising children with sickle cell disease at the intersection of race, gender, and illness stigma.
Sickle cell disease (SCD) is the most prevalent genetic hematological disorder worldwide (Baskin et al., 2000), predominantly affecting populations of West African and African Caribbean descent, as well as populations of Asian, Middle Eastern, and Mediterranean origins (Ahmad & Atkin, 1996). SCD affects one in 400 to 500 African...

Pulmonary function declines early in sickle cell disease.
TORONTO -- Abnormalities in lung function already are present at age 8 years in children with sickle cell disease, and the subsequent rate of decline is between 2% and 3% per year, according to one study. "We were aware from cross-sectional studies that children with sickle cell...

Sickle cell disease patients should beware of heroin pumps.
A new report published by the UK's National Confidential Enquiry into Patient outcome and Death (NCEPOD) has raised concerns about the use of morphine and its derivatives in the care of sickle cell disease patients. The report's conclusions support a long-standing campaign by some African and other doctors who...

Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease.
SAN MATEO, Calif., Jan. 9 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for use of its lead compound A-001 in hospitalized patients with sickle cell disease....

New Hope for Children With Sickle Cell Disease.
For more information on this report or to view the video news release: http://www.prnewswire.com/broadcast/5049/5049_consumer.html MEMPHIS, Tenn., Aug. 2 /PRNewswire/ -- There is new hope for the 70,000 Americans currently living with sickle cell disease: the use of hydroxyurea, a drug that for the...

FLOCOR Granted 'Fast Track' Status By FDA For Treatment of Acute Chest Syndrome in Sickle Cell Disease.
ATLANTA, June 14 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR) today announced that its experimental product, FLOCOR (purified poloxamer 188), has been designated as a "fast track" product by the United States Food and Drug Administration (FDA) for treatment of acute chest syndrome associated with sickle cell disease....

Lung function declines early in sickle cell.
TORONTO -- Lung function abnormalities are present at age 8 years in children with sickle cell disease, and the subsequent rate of decline is between 2% and 3% a year, according to new data. "We were aware [of the lung function abnormalities] from cross-sectional studies, but they...

Sickle Cell Disease Symposium Aims to Interest High School Students in Biomedical Research.
ORLANDO, Fla., Dec. 6 /PRNewswire/ -- The American Society of Hematology (ASH(TM)), the world's largest professional society of blood specialists, will host a special symposium for high school students as part of its 48th Annual Meeting to help stimulate an interest in hematology, the biological sciences, and medical research....

Sickle cell disease and trait: an increase in trabecular spacing, a case study.
Introduction Sickle cell anemia, the most common inherited blood disorder in people in the United States, affects about 72,000, among which approximately one in five-hundred are of African descent. (1) About 10% of people of African descent carry the gene, and about one in one hundred Hispanics...

Iron deficiency anaemia in sickle cell disorders in India.
Background & objectives: Iron deficiency anaemia (IDA) is uncommon in individuals with sickle cell disease (SCD) because of availability of an adequate iron source potentially from increased red cell turnover and from blood transfusions. Also, iron deficiency anaemia can often go unnoticed because the sickle cell disease patients are...